Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Literature
1.
Dores GM, Landgren O, McGlynn KA, Curtis RE, Linet MS, Devesa SS (2009) Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the United States, 1992-2004. Br J Haematol 144:86–94CrossRef
2.
Shih LY, Dunn P, Leung WM, Chen WJ, Wang PN (1995) Localised plasmacytomas in Taiwan: comparison between extramedullary plasmacytoma and solitary plasmacytoma of bone. Br J Cancer 71:128–133CrossRef
3.
Radman I, Sucić M, Serventi-Seiwerth R, Boban D, Marković-Glamocak M, Ries S, Gjadrov-Kuvezdić K, Petković D, Jakić-Razumović J, Sćukanec-Spoljar M, Seiwerth S, Sucić Z, Papa J (2005) Patient with immunoproliferative disease and lung carcinoma: a case report. Diagn Cytopathol 32(2):97–102CrossRef
4.
Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ, Lebovic D, Dhodapkar M, Avigan D, Chapuy B, Ligon AH, Freeman GJ, Rodig SJ, Cattry D, Zhu L, Grosso JF, Bradley Garelik MB, Shipp MA, Borrello I, Timmerman J (2016) Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol 34:2698–2704CrossRef
5.
Yamaguchi O, Kaira K, Hashimoto K, Mouri A, Miura Y, Shiono A, Nishihara F, Murayama Y, Noda SE, Kato S, Kobayashi K, Kagamu H (2019) Radiotherapy is an independent prognostic marker of favorable prognosis in non-small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab. Thorac Cancer T 10:992–1000CrossRef
Metadata
Title
Unexpected response of extramedullary plasmacytoma in patients with lung cancer who received nivolumab
Authors
Ou Yamaguchi
K. Kaira
Y. Nakamura
H. Kagamu
Publication date
01-12-2019
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 12/2019
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-019-03832-6

Other articles of this Issue 12/2019

Annals of Hematology 12/2019 Go to the issue

Original Article

Genetic modulators of fetal hemoglobin expression and ischemic stroke occurrence in African descendant children with sickle cell anemia

Original Article

CRISPR/Cas9 gene correction of HbH-CS thalassemia-induced pluripotent stem cells

Original Article

Socioeconomic Position is Positively Associated with Monoclonal Gammopathy of Undetermined Significance in a Population-based Cohort Study

Original Article

Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission—a multi-center historical control study

Original Article

Outcomes of allogeneic stem cell transplantation for DLBCL: a multi-center study from the Kyoto Stem Cell Transplantation Group

Letter to the Editor

Response to interferon treatment in essential thrombocythemia with inv(3)(q21q26)

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits